New insights into chronic inducible urticaria

Area of Science:

• Urticaria research
• Immunology
• Dermatology

Background:

• Chronic inducible urticaria (CIndU) encompasses difficult-to-manage conditions causing recurrent wheals and angioedema triggered by specific factors.
• CIndU significantly impacts patients' quality of life, necessitating improved diagnostic and therapeutic strategies.
• Advances in understanding CIndU pathogenesis and the development of patient-reported outcome measures have enhanced patient evaluation.

Purpose of the Study:

• To review recent findings on the pathogenesis, diagnosis, and treatment of Chronic inducible urticaria (CIndU).
• To discuss novel potential therapeutic targets for developing more effective CIndU therapies.
• To provide an updated overview of management strategies for CIndU patients.

Main Methods:

• Literature review of recent findings on CIndU.
• Analysis of current diagnostic approaches, including provocation tests.
• Evaluation of existing and emerging treatment options for CIndU.

Main Results:

• Second-generation non-sedating H1-antihistamines are the primary licensed treatment but often lack efficacy.
• Off-label use of omalizumab shows good outcomes across various CIndU subtypes.
• Emerging therapies, initially studied in chronic spontaneous urticaria, show promise for CIndU treatment.

Conclusions:

• Despite advances, CIndU remains challenging to treat, with current therapies having limitations.
• Provocation tests are crucial for diagnosing specific CIndU subtypes.
• Further research into novel targets and therapies is essential for improving CIndU management and patient QoL.